Fecal microbiota transplantation restores gut microbiota diversity and butyrogenic taxa more effectively than fidaxomicin in recurrent Clostridioides difficile infection
Abstract
IntroductionRecurrent Clostridioides difficile infection (rCDI) is commonly treated with fidaxomicin or fecal microbiota transplantation (FMT). Although both achieve high clinical cure rates, their differential impact on gut microbiota composition and function remain uncharacterized.MethodsTwenty-seven patients from the phase III ICD-01 trial (EudraCT 2020-004591-17) were included, 12 of them received FMT and the remaining 15 received fidaxomicin. Stool samples were collected at baseline and 8 weeks post-treatment. Microbiota composition was assessed by shotgun metagenomics and functionality by short-chain fatty acids (SCFAs) quantification. Metatranscriptomic sequencing was additionally performed in a subset of 7 patients (3 FMT and 4 fidaxomicin). Differential abundance, alpha/beta–diversity, resistome, and toxin-gene burden and expression were evaluated.ResultsNo clinical recurrence occurred at 8 weeks in either group, however alpha–diversity (species richness, Shannon and Simpson indexes) only increased significantly after FMT. Both treatments induced significant shifts in beta–diversity. FMT produced marked enrichment of butyrate-producing taxa, including Ruminococcus, Oscillospiraceae, Fusicatenibacter, Anaerostipes, Roseburia and Dorea. Fidaxomicin expanded Blautia while reducing Enterobacteriaceae, Veillonella and Parvimonas. C. difficile abundance did not change significantly, although their toxin genes (tcdA/tcdB) decreased after both interventions, as well as the total abundance of antibiotic-resistance genes. Among the significant changes in fecal SCFA concentrations, increases in acetate, isovalerate, and hexanoate were observed in both groups; butyrate and isovalerate increased most after FMT, whereas propionate, isobutyrate, and valerate only with fidaxomicin.ConclusionFMT drives substantially greater restoration of microbial diversity and a selective expansion of butyrogenic taxa than fidaxomicin.
Related
- The Microbiota Dictates Vendor-Derived Differences in a Murine Clostridioides difficile Infection Model
- An endolysin-expressing probiotic attenuates Clostridioides difficile infection in germ-free and dysbiotic microbiota-associated mice
- Mechanistic prediction of fecal microbiota transplant engraftment and Clostridioides difficile colonization resistance with μODE
- Longitudinal Metaproteomic and Lysine Crotonylation Remodeling Defines Clinical Response to Fecal Microbiota Transplantation in Ulcerative Colitis
- Current status of research on fecal microbiota transplantation in the postoperative management of inflammatory bowel disease
BibTeX
@article{ballestero2026fecal,
title = {{Fecal microbiota transplantation restores gut microbiota diversity and butyrogenic taxa more effectively than fidaxomicin in recurrent Clostridioides difficile infection}},
author = {Luna Ballestero and Raquel Barbero-Herranz and Celia Morales and Esther Palacios and Ana Moreno-Blanco and Rafael Cantón and Patricia del Río and Juan Basterra and José Avendaño-Ortiz and Rosa del Campo},
journal = {Frontiers in Microbiology},
year = {2026},
month = nov,
doi = {10.3389/fmicb.2026.1982505},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1982505},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fecal microbiota transplantation restores gut microbiota diversity and butyrogenic taxa more effectively than fidaxomicin in recurrent Clostridioides difficile infection
AU - Luna Ballestero
AU - Raquel Barbero-Herranz
AU - Celia Morales
AU - Esther Palacios
AU - Ana Moreno-Blanco
AU - Rafael Cantón
AU - Patricia del Río
AU - Juan Basterra
AU - José Avendaño-Ortiz
AU - Rosa del Campo
PY - 2026
DA - 2026/11/04
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1982505
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1982505
AB - IntroductionRecurrent Clostridioides difficile infection (rCDI) is commonly treated with fidaxomicin or fecal microbiota transplantation (FMT). Although both achieve high clinical cure rates, their differential impact on gut microbiota composition and function remain uncharacterized.MethodsTwenty-seven patients from the phase III ICD-01 trial (EudraCT 2020-004591-17) were included, 12 of them received FMT and the remaining 15 received fidaxomicin. Stool samples were collected at baseline and 8 weeks post-treatment. Microbiota composition was assessed by shotgun metagenomics and functionality by short-chain fatty acids (SCFAs) quantification. Metatranscriptomic sequencing was additionally performed in a subset of 7 patients (3 FMT and 4 fidaxomicin). Differential abundance, alpha/beta–diversity, resistome, and toxin-gene burden and expression were evaluated.ResultsNo clinical recurrence occurred at 8 weeks in either group, however alpha–diversity (species richness, Shannon and Simpson indexes) only increased significantly after FMT. Both treatments induced significant shifts in beta–diversity. FMT produced marked enrichment of butyrate-producing taxa, including Ruminococcus, Oscillospiraceae, Fusicatenibacter, Anaerostipes, Roseburia and Dorea. Fidaxomicin expanded Blautia while reducing Enterobacteriaceae, Veillonella and Parvimonas. C. difficile abundance did not change significantly, although their toxin genes (tcdA/tcdB) decreased after both interventions, as well as the total abundance of antibiotic-resistance genes. Among the significant changes in fecal SCFA concentrations, increases in acetate, isovalerate, and hexanoate were observed in both groups; butyrate and isovalerate increased most after FMT, whereas propionate, isobutyrate, and valerate only with fidaxomicin.ConclusionFMT drives substantially greater restoration of microbial diversity and a selective expansion of butyrogenic taxa than fidaxomicin.
SN - 1664-302X
ER -